STOCK TITAN

[SCHEDULE 13G] Sonnet BioTherapeutics Holdings, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Calculations of the percentage set forth in Row 11 are based on the quotient obtained by dividing (a) the number of shares of Sonnet BioTherapeutics Holdings, Inc. Common Stock beneficially owned by the Reporting Persons as set forth in Row 9 by (b) the 6,264,165 shares of Common Stock outstanding as of July 18, 2025, as reported in the Issuer's current report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 18, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Calculations of the percentage set forth in Row 11 are based on the quotient obtained by dividing (a) the number of shares of Sonnet BioTherapeutics Holdings, Inc. Common Stock beneficially owned by the Reporting Persons as set forth in Row 9 by (b) the 6,264,165 shares of Common Stock outstanding as of July 18, 2025, as reported in the Issuer's current report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 18, 2025.


SCHEDULE 13G



Republic Digital Opportunistic Digital Assets Master Fund, Ltd.
Signature:/s/ Joseph Naggar
Name/Title:Joseph Naggar, Authorized Signatory
Date:07/25/2025
Joseph Naggar
Signature:/s/ Joseph Naggar
Name/Title:Joseph Naggar
Date:07/25/2025
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement, dated July 25, 2025, by and between Republic Digital Opportunistic Digital Assets Master Fund, Ltd. and Joseph Naggar.

Sonnet Biotherapeutc Hldng Inc

NASDAQ:SONN

SONN Rankings

SONN Latest News

SONN Latest SEC Filings

SONN Stock Data

23.83M
6.53M
4.4%
5.56%
27.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON